ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Everolimus

Also written as “everolimus”, “RAD001” and “Everolimus (RAD001)”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Tuberous Sclerosis · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors, led by 4 companies.

Drug pageEverolimus: every studyAll 618 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 8, 2005125 company-led studies, 2 open or runningNext primary completion: Feb 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis1201 open or runningphase 4since Sep 8, 2005Oct 6, 2004Feb 26, 2027phase 3 · NCT02962414
Chong Kun Dang Pharmaceuticalits history only21 open or runningphase 4since Apr 29, 2021Apr 29, 2021Dec 2030phase 4 · NCT06942156
iOMEDICOits history only20 open or runningphase 4since Dec 23, 2010Dec 23, 2010none ahead
Chiesi Farmaceuticiits history only10 open or runningphase 2since Oct 28, 2016Oct 28, 2016none ahead

Also a collaborator on its studies: Merck, Pfizer, Cromsource and Roche Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Apr 8, 2009.

  1. Jan 11, 2013Phase 2 study in Breast NeoplasmsNCT01783444 · 309 enrolled · United States, Argentina, Australia and more
  2. Feb 7, 2013Phase 4 study in NeoplasmsNCT01789281 · 34 enrolled · United States, Czechia, Italy and more
  3. Apr 18, 2013Phase 3 study in Rejection, PsychologyNCT01843348 · 612 enrolled · France, Germany
  4. Dec 17, 2013Phase 2 study in NeoplasmsNCT02017860 · 4 enrolled · Japan
  5. Feb 20, 2014Phase 2 study in Advanced Breast CancerNCT02069093 · 92 enrolled · United States
  6. Mar 20, 2014Phase 3 study in Liver TransplantationNCT02115113 · 78 enrolled · Italy
  7. Dec 1, 2014Phase 4 study in Body WeightNCT02338609 · 15 enrolled · United States, Belgium, Russian Federation
  8. Jun 1, 20162 phase 4 studiesNCT02864706, NCT02842749
  9. Nov 9, 2016Phase 3 study in Tuberous SclerosisNCT02962414 · 206 enrolled · United States, Australia, Belgium and more
  10. Jun 1, 2017Phase 3 study in Breast NeoplasmsNCT03176238 · 235 enrolled · Australia, India, Indonesia and more
  11. Sep 15, 2017Phase 2 study in Breast NeoplasmsNCT03312738 · 159 enrolled · China
  12. May 3, 2018Phase 4 study in AngiomyolipomaNCT03525834 · 40 enrolled · China
  13. Feb 16, 2022Phase 4 study in AngiomyolipomaNCT05252585 · 10 enrolled · Taiwan
  14. Nov 12, 2026Primary completion moved from 2026-12-30 to 2027-02-26Date moved laterphase 3 · +2 months · NCT02962414

Ahead

  1. Feb 26, 2027Primary completion: phase 3 study in Tuberous SclerosisNCT02962414

TargetBeta

FKBP1A →read by rule
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule

Other programs on FKBP1A

ProgramCompanyFurthest phaseStudies
TacrolimusruleAstellas Pharmaphase 4182

Studies

The newest 60 of 120 Novartis leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT05252585Angiomyolipoma · Taiwan4CompletedOct 13, 202610
NCT03525834Angiomyolipoma · China4CompletedSep 25, 202040
NCT03312738Breast Neoplasms · China2CompletedApr 25, 2022159
NCT03176238Breast Neoplasms · Australia, India, Indonesia and more3CompletedJan 29, 2019235
NCT02962414Tuberous Sclerosis · United States, Australia, Belgium and more3Active, not recruitingFeb 26, 2027206
NCT02842749Pancreatic Neuroendocrine Tumors · China4CompletedFeb 22, 202461
NCT02864706Graft vs Host Disease · Denmark, Norway, Sweden4CompletedSep 25, 201795
NCT02338609Body Weight · United States, Belgium, Russian Federation4CompletedDec 18, 202315
NCT02115113Liver Transplantation · Italy3CompletedSep 30, 201678
NCT02069093Advanced Breast Cancer · United States2CompletedMar 201692
NCT02017860Neoplasms · Japan2CompletedApr 25, 20194
NCT01843348Rejection, Psychology · France, Germany3CompletedMar 23, 2016612
NCT01789281Neoplasms · United States, Czechia, Italy and more4CompletedAug 28, 202034
NCT01783444Breast Neoplasms · United States, Argentina, Australia and more2CompletedJul 2, 2018309
NCT01743560Breast Neoplasms · United Kingdom4CompletedAug 15, 201652
NCT01713946Tuberous Sclerosis Complex-associated Refractory Seizures · United States, Argentina, Australia and more3CompletedOct 25, 2017366
NCT01698918Breast Neoplasms · United States, Argentina, Brazil and more2CompletedDec 17, 2015202
NCT01626222Breast Neoplasms · Germany3CompletedNov 2013301
NCT01625377Liver Transplantation · France3CompletedMar 2015188
NCT01595009Neuroendocrine Tumors · Germany4CompletedAug 9, 2016246
NCT01594268Kidney Transplant · Korea, Republic of4CompletedOct 201354
NCT01590199Neuroendocrine Tumors · Germany1CompletedSep 11, 201818
NCT01563354Carcinoma, Neuroendocrine · Denmark, France, Germany and more2CompletedFeb 10, 2020124
NCT01551212Liver Transplantation · Germany4CompletedAug 8, 2017339
NCT01514448Carcinoma, Renal Cell · Germany4CompletedApr 1, 201629
NCT01524783Neuroendocrine Tumors · United States, Austria, Belgium and more3CompletedNov 28, 2014302
NCT01491672Carcinoma, Renal Cell · United States, Argentina, Brazil and more2CompletedMay 2015134
NCT01545817Carcinoma, Renal Cell · Australia, Korea, Republic of2TerminatedNov 18, 201674
NCT01596062Renal Transplantation · France2CompletedMar 201316
NCT01404325Lung Transplantation · Germany3CompletedJan 5, 2017130
NCT01374451Adenoma, Islet Cell · United States, Argentina, Australia and more2TerminatedFeb 2015160
NCT01544491Death · United States, Argentina, Brazil and more3CompletedOct 3, 2016106
NCT01379521Carcinoma, Hepatocellular · Hong Kong, Taiwan, Thailand2TerminatedJun 201565
NCT01365468Neurofibroma, Plexiform · Israel2TerminatedApr 20159
NCT01324492Lung Neuroendocrine Neoplasm · China1CompletedJun 201416
NCT01317615Carcinoma, Large Cell · Germany4CompletedMar 201549
NCT01275222Gastrointestinal Stromal Tumors · United States, Belgium, France and more2CompletedSep 3, 2008117
NCT01263353Carcinoid Tumor · Germany1CompletedMar 201436
NCT01231659Breast Neoplasms · Israel2CompletedNov 20, 201272
NCT01217177Uterine Cervical Neoplasms · Brazil1CompletedApr 201414
NCT01269684Kidney Transplantation · Switzerland4WithdrawnAug 20080
NCT01206764Carcinoma, Renal Cell · Algeria, Egypt, India and more4CompletedJun 6, 2017143
NCT01266148Renal Function and Chronic Allograft Vasculopathy · Denmark, Norway, Sweden4CompletedDec 2012115
NCT01169701Hypertrophy, Left Ventricular · Spain4CompletedMar 201471
NCT01152801Carcinoma, Renal Cell · China1CompletedDec 201364
NCT01114529Kidney Transplantation · Argentina, Australia, Austria and more3CompletedOct 30, 2014828
NCT01150097Liver Transplant Recipient · United States, Argentina, Australia and more3CompletedMay 3, 2013284
NCT01079143Renal Interstitial Fibrosis · France3CompletedJun 2012194
NCT01059318Lymphangioleiomyomatosis · United States, France, Italy2CompletedJun 201224
NCT01035229Carcinoma · United States, Australia, Austria and more3CompletedOct 2013546
NCT01023815de Novo Kidney Transplant Recipients · Italy3CompletedJul 2012330
NCT01022996Hodgkin Disease · United States2CompletedNov 201457
NCT01025817Kidney Transplant · United States, Canada3CompletedMar 2013613
NCT01017029Cardiac Transplantation · Italy4CompletedDec 2013182
NCT01007942Breast Neoplasms · United States, Argentina, Australia and more3CompletedJun 2015569
NCT00968591Hepatic Insufficiency · Germany, Russian Federation, Singapore1CompletedNov 201034
NCT00965094Kidney Failure, Chronic · Israel4CompletedJun 201336
NCT00956293Renal Transplantation · Germany4TerminatedMar 2013207
NCT00903175Carcinoma, Renal Cell · United States, Argentina, Australia and more2CompletedMay 2015471
NCT00879333Stomach Neoplasms · United States, Argentina, Australia and more3CompletedJan 2014656

How it is read

Names in the registry

  • “Everolimus”, 64 entries
  • “everolimus”, 16 entries
  • “RAD001”, 16 entries
  • “Everolimus (RAD001)”, 15 entries
  • “Everolimus (reduced tacrolimus)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.